Navegando por Autor "Sarris, Jerome"

Agora exibindo 1 - 3 de 3

Moderators of ayahuasca’s biological antidepressant action
(Frontiers Media SA, 2022-12) Sousa Júnior, Geovan Menezes de; Tavares, Vagner Deuel de Oliveira; Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nóbrega de; Fontes, Fernanda Palhano Xavier de; Soares, Bruno Lobão; Freire, Fúlvio Aurélio de Morais; Nunes, Emerson Arcoverde; Oliveira, João Paulo Maia de; Perkins, Daniel; Sarris, Jerome; Araujo, Draulio Barros de; Coelho, Nicole Leite Galvão
Introduction: The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol (SC), serum interleukin 6 (IL-6), plasma C-reactive protein (CRP), and salivary cortisol awakening response (CAR). Methods: Results were analyzed 2 days after the psychedelic intervention (ayahuasca) versus placebo in both patients with treatment-resistant depression and healthy volunteers. These measures were assessed as part of a randomized double-blinded, placebo-controlled trial (n = 72). Results: Results revealed that larger reductions of depressive symptoms during the dosing session significantly moderated higher levels of SC in patients. Whereas lesser changes in salivary cortisol levels during the ayahuasca intervention were related to higher BDNF levels in patients with a larger clinical response in the reduction in depressive symptoms. No moderator was found for patient's CAR, IL-6, and CRP responses to ayahuasca and for all biomarker responses to ayahuasca in healthy controls and in the placebo group. Discussion: In summary, some specific emotional and physiological parameters during experimental ayahuasca session were revealed as critical moderators of the improvement of major depression biomarkers, mainly BDNF and SC two days after ayahuasca intake. These findings contribute to paving the way for future studies investigating the biological antidepressant response to psychedelic therapy
Pathophysiology of major depression by clinical stages
(Frontiers Media SA, 2021-08-05) Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nobrega; Sousa Júnior, Geovan Menezes de; Miguel, Mario André Leocadio; Fontes, Fernanda Palhano Xavier de; Araujo, Draulio Barros de; Soares, Bruno Lobão; Oliveira, João Paulo Maia de; Nunes, Emerson Arcoverde; Hallak, Jaime Eduardo Cecilio; Schuch, Felipe Barreto; Sarris, Jerome; Galvão-Coelho, Nicole Leite
The comprehension of the pathophysiology of the major depressive disorder (MDD) is essential to the strengthening of precision psychiatry. In order to determine the relationship between the pathophysiology of the MDD and its clinical progression, analyzed by severity of the depressive symptoms and sleep quality, we conducted a study assessing different peripheral molecular biomarkers, including the levels of plasma C-reactive protein (CRP), serum mature brain-derived neurotrophic factor (mBDNF), serum cortisol (SC), and salivary cortisol awakening response (CAR), of patients with MDD (n = 58) and a control group of healthy volunteers (n = 62). Patients with the first episode of MDD (n = 30) had significantly higher levels of CAR and SC than controls (n = 32) and similar levels of mBDNF of controls. Patients with treatment-resistant depression (TRD, n = 28) presented significantly lower levels of SC and CAR, and higher levels of mBDNF and CRP than controls (n = 30). An increased severity of depressive symptoms and worse sleep quality were correlated with levels low of SC and CAR, and with high levels of mBDNF. These results point out a strong relationship between the stages clinical of MDD and changes in a range of relevant biological markers. This can assist in the development of precision psychiatry and future research on the biological tests for depression
Potential biomarkers of major depression diagnosis and chronicity
(2021-09-29) Galvão, Ana Cecília de Menezes; Almeida, Raissa Nobrega; Sousa Júnior, Geovan Menezes de; Leocadio-Miguel, Mário André; Fontes, Fernanda Palhano Xavier de; Araujo, Draulio Barros de; Lobão-Soares, Bruno; Maia-de-Oliveira, João Paulo; Nunes, Emerson Arcoverde; Hallak, Jaime Eduardo Cecilio; Sarris, Jerome; Galvão-Coelho, Nicole Leite
Molecular biomarkers are promising tools to be routinely used in clinical psychiatry. Among psychiatric diseases, major depression disorder (MDD) has gotten attention due to its growing prevalence and morbidity. We tested some peripheral molecular parameters such as serum mature Brain-Derived Neurotrophic Factor (mBDNF), plasma C-Reactive Protein (CRP), serum cortisol (SC), and the salivary Cortisol Awakening Response (CAR), as well as the Pittsburgh sleep quality inventory (PSQI), as part of a multibiomarker panel for potential use in MDD diagnosis and evaluation of disease’s chronicity using regression models, and ROC curve. For diagnosis model, two groups were analyzed: patients in the first episode of major depression (MD: n = 30) and a healthy control (CG: n = 32). None of those diagnosis models tested had greater power than Hamilton Depression Rating Scale-6. For MDD chronicity, a group of patients with treatment-resistant major depression (TRD: n = 28) was tested across the MD group. The best chronicity model (p < 0.05) that discriminated between MD and TRD included four parameters, namely PSQI, CAR, SC, and mBDNF (AUC ROC = 0.99), with 96% of sensitivity and 93% of specificity. These results indicate that changes in specific biomarkers (CAR, SC, mBDNF and PSQI) have potential on the evaluation of MDD chronicity, but not for its diagnosis. Therefore, these findings can contribute for further studies aiming the development of a stronger model to be commercially available and used in psychiatry clinical practice

SIGAA

Navegando por Autor "Sarris, Jerome"